FeedPosted Nov 9th 2009 10:10AM by Jim Cramer (RSS feed)
Filed under: Market matters, Abbott Laboratories (ABT), Aetna Inc (AET), CIGNA Corp (CI), Gilead Sciences (GILD), Stocks to Buy, Cramer on BloggingStocks
TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge. Nancy Pelosi has now said her piece. The most unpopular Speaker of the House in the history of Wall Street has gotten her precious health care legislation through the House after ramming through a stimulus package that had far too little infrastructure and far too much pay raise for municipal and state workers, the most powerful interest group in the country.
But this time the Senate sees through it, and the politicians -- despite Pelosi's insistence that Tuesday's election went her way -- know better. There are pages after pages after pages in this bill that look threatening. But here's the rub: This bill's public option, the one that is supposed to be a killer to everything health care, should affect no more than 6 million people over a 10-year period, according to the Congressional Budget Office. In order to get 60 votes in the Senate, even that may prove to be too powerful an option.
Continue reading Cramer on BloggingStocks: Pelosi can't kill the health care sector
Posted Nov 5th 2009 1:10PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Gilead Sciences (GILD), Stocks to Buy
"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.
The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.
"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.
Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug
Posted Sep 25th 2009 1:00PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Gilead Sciences (GILD), Stocks to Buy
"Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green.
The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects."
"Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.)
Continue reading Gilead (GILD): 'A stock for all seasons'
Posted Jul 17th 2009 12:20PM by Mark Fightmaster (RSS feed)
Filed under: Gilead Sciences (GILD)
Yesterday,
Gilead Sciences (NASDAQ:
GILD) announced that it
entered a license and collaboration agreement with Tibotec Pharmaceuticals. The two firms will combine to develop and commercialize a new once-daily, fixed-dose treatment for HIV. GILD's CEO John Martin noted, "Gilead and Tibotec share a strong focus on bringing safe and effective treatment options to people living with HIV/AIDS."
If the collaboration is approved, GILD will assume the lead in manufacturing, registration, distribution, and commercialization of a fixed-dose combination of Truvada and rilpivirine. GILD will not be responsible for the commercialization of this combination in the developing world and Japan, which will be handled by Tibotec. The two companies will work toward an agreement to market the combination in the developing world.
Continue reading Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals
Posted Jul 11th 2009 9:00AM by Michael Shulman (RSS feed)
Filed under: Gilead Sciences (GILD), Stocks to Buy
Few would argue with the claim that Gilead Sciences (NASDAQ: GILD) is the best-managed biopharma company on the planet.
It dominates the HIV treatment market and gets a 19%-plus royalty on Tamiflu, which is used to treat H1N1 (swine) flue. Gilead also has several drugs on or headed for the market to treat pulmonary disease and hard-to-treat high blood pressure.
Your best strategy for life-changing profits?
Buy the stock and sell the calls (then use the cash to buy puts on the market, which is headed down further.) Or buy long-term calls and keep an eye on them.
Next: Biotech Stock #2
Posted May 21st 2009 11:10AM by Laurie Pasternack (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Target Corp. (TGT), Campbell Soup (CPB), CIGNA Corp (CI), Safeway Inc (SWY), Analyst initiations, Gilead Sciences (GILD), Freep't McMoRan Copper (FCX), Suntech Power Hldgs ADS (STP)
.gif)
Analyst upgrades:
- UBS upgraded Target (NYSE: TGT) to Buy from Neutral and raised its price target to $52 from $45 citing reduced inventories, some credit stability, and an improved back-to-school period.
- Credit Suisse said concerns regarding Safeway's (NYSE: SWY) price position are overblown and that earnings risk is limited. The firm upgraded shares to Outperform from Neutral and raised the target price to $25 from $22.
- Oppenheimer upgraded Canadian Solar (NASDAQ: CSIQ) to Outperform from Perform as it believes the story is underappreciated following the recent sector rally. The firm has a $14 price target on the stock.
- CME Group (NASDAQ: CME) was upgraded to buy from Neutral at Goldman.
- Freeport McMoRan (NYSE: FCX) was upgraded to Overweight from Neutral at JP Morgan.
- Gilead Sciences (NASDAQ: GILD) was upgraded to Buy from Neutral at FTN Equity.
Continue reading Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG
Posted Apr 27th 2009 1:00PM by Melly Alazraki (RSS feed)
Filed under: Walgreen Co (WAG), Novartis AG ADS (NVS), Baxter Intl (BAX), CVS Corp (CVS), Hormel Foods (HRL), Tyson Foods'A' (TSN), Smithfield Foods (SFD), Gilead Sciences (GILD), Agriculture
I remember Toronto during SARS. As one of the harder hit areas, it was not a happy place. It was the end of winter, but that miserable, cold winter just didn't want to end. People walked the streets in a gloomy haze, afraid to take the subway and giving dirty looks to anyone brazen enough to cough in public. Worse, I couldn't even visit a friend in the hospital. All things considered though, in global pandemic terms, it was over relatively quickly. Let's hope swine flu will be the same.
In the meantime, let's put on our investors hats and see what's in store for some stocks:
Travel and tourist stocksThis is one of the worst hit areas, especially airlines, as people may cancel their travel plans. For example,
AMR Corp. (NYSE:
AMR) traded over 9 percent lower an hour after the open.
Royal Caribbean Cruises (NYSE:
RCL) was down over 15 percent. In fact UBS downgraded these airlines and hotels this morning: AMR,
Continental Airlines (NYSE:
CAL),
Host Hotels and Resorts (NYSE:
HST),
Lasalle Hotel Properties (NYSE:
LHO),
Marriott (NYSE:
MAR),
United Airlines (NASDAQ:
UAUA),
US Airways (NYSE:
LCC).
Carnival Cruise Lines (NYSE:
CCL) also declined considerably. Best to stay away from the sector.
Continue reading Don't fear the swine flu . . . trade it
Posted Apr 22nd 2009 1:20PM by Laurie Pasternack (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Ford Motor (F), General Motors (GM), Caterpillar (CAT), Colgate-Palmolive (CL), Dean Foods (DF), US Airways Group (LCC), Lockheed Martin (LMT), Analyst initiations, Broadcom Corp'A' (BRCM), Gilead Sciences (GILD), Andersons Inc (ANDE)
.gif)
Analyst upgrades:
- Merriman upgraded Dendreon (NASDAQ: DNDN) to Buy from Neutral on expectations shares will react positively to the full IMPACT data release on April 28. The firm thinks Provenge could represent the first cancer immunotherapy approved in the U.S. and raised its valuation range on the stock to $33-$34 from $18-$19.
- Piper Jaffray upgraded Andersons (NASDAQ: ANDE) as it believes the valuation is attractive, investor expectations are low, and the company's fertilizer and rail segments could recovery in FY10. The firm has a $19 target on shares. Goldman upgraded the auto sector to Neutral from Cautious and added Ford (NYSE: F) to its Conviction Buy list. The analyst does not believe Ford will have to declare bankruptcy and sees the company benefiting from Chrysler share declines and GM's (NYSE: GM) reduced product offerings. Ford's price target is $6
- Banc of America/Merrill upgraded U.S. Airways (NYSE: LCC) to Buy from Underperform.
- Broadcom (NASDAQ: BRCM) was upgraded to Equal Weight from Underweight at Morgan Stanley.
- Caterpillar (NYSE: CAT) was raised to Overweight from Neutral at JP Morgan.
Continue reading Analyst upgrades, downgrades and initiations: DNDN, ANDE, the auto sector, DGX, MTB, ADVS, ITG, MF and PCLN
Posted Apr 20th 2009 10:30AM by Jim Cramer (RSS feed)
Filed under: PepsiCo (PEP), Ford Motor (F), General Motors (GM), Market matters, Walgreen Co (WAG), Citigroup Inc. (C), Target Corp. (TGT), Brinker Intl (EAT), Penney (J.C.) (JCP), Abbott Laboratories (ABT), American Express (AXP), AutoNation Inc (AN), AutoZone Inc (AZO), Centex Corp (CTX), Charles Schwab Corp (SCHW), Kellogg Co (K), Hershey Co (HSY), Sears Holdings (SHLD), CVS Corp (CVS), Gap Inc (GPS), General Mills (GIS), Procter and Gamble (PG), Yum Brands (YUM), Kohl's Corp (KSS), Johnson Controls (JCI), Gilead Sciences (GILD), Nordstrom, Inc (JWN), Unilever ADR (UL), Jones Apparel Group (JNY), Cramer on BloggingStocks, Recession, E*TRADE (ETFC)
TheStreet.com's Jim Cramer is seeing signs of a coming boom, but he's still being cautious here. If you had to define the early cycle, if you had to outline what stocks should be soaring coming out of a recession into a boom and which ones should be faltering, you would have to say the action in this market in the last month is the quintessential behavioral pattern.
What are the components of the early cycle? First, it's the homebuilders. As is typical coming out of a recession, the stocks precede the bottom of housing. That's exactly what's happening with the lowest permits and highest affordability and best mortgage rates and massive inventory. Everywhere, except on Wall Street reporting, the bottom is bursting out. When you read the lead story in the Sunday Philadelphia Inquirer, and it is all about the thousands of prospective homebuyers heading south to pick up condos and homes for half of what they were worth two years ago -- or even less -- and you know that virtually no one has broken ground in the Sunshine State in a year, you can bet that the bottom's actually behind us. This housing market has wiped out all but the most stable private builders and even the public ones are merging as we know from
Pulte (NYSE:
PHM) (
Cramer's Take) and
Centex (NYSE:
CTX) (
Cramer's Take). So, in the next cycle, you can see some profitability developing year over year even though the new homes don't have much margin because the foreclosed homes next door are going for a song. And don't believe this won't change the dynamic of future foreclosures. In most areas, rent is higher than the interest on mortgages, so you will find that second or third job needed to stay in your home. The incentive structure's radically different than a year ago.
Continue reading Cramer on BloggingStocks: The seductive pull of the early cycle
Posted Apr 3rd 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: Market matters, Gilead Sciences (GILD), Cramer on BloggingStocks, Financial Crisis
TheStreet.com's Jim Cramer says it'd be easy to follow the herd and doubt the staying power of this rally, but that's not his style.
People think I am nuts . . . even more than usual. All they can talk about at the cocktail parties and the lunches and on the Street is how bad things are. They want to hide in gold. They want to hide under the bed. They think that every move is false and every rally must be sold. The negativity is so thick that even my closest friends think that I am being wishful about the turn. Oh, and heaven forbid there would be one positive article in The Wall Street Journal about this market. Just one!
Continue reading Cramer on BloggingStocks: Sticking to my guns
Next Page »
Last week, 
Last year, as the market sank, one group actually went up -- large-cap, cashflow positive biotech and genomics companies.
Why is gold marching higher? Ask the central bankers
Newspaper ad revenue of 28%, 8 quarters of double-digit drops
Closing Bell: Earnings working against stocks (BCRX, DELL, DHI, INTC, LEAP, PCS)
